Abstract
Objective To identify Zinc finger MYND-type containing 8 (ZMYND8) as a direct target for glucocorticoid receptor (GR) and illustrate the correlations between ZMYND8 and clinical characteristics of prostate cancer. Methods Bioinformatics software and Western blotting were used to analyze the relationship between ZMYND8 and GR in GR-knock-out prostate cancer cells. In order to evaluated the correlation of ZMYND8 with clinical characteristics, immunohistochemistry was used to detect ZMYND8 protein in 80 cases of prostate cancer and benign prostate hyperplasia (BPH) tissues. Results ZMYND8 functioned as a cancer promoter via the regulation of GR, and the expression of ZMYND8 protein was significantly increased in prostate cancer and metastatic tumor tissue (immunoreactivity score: no cancer: 5.700±2.054, cancer: 7.340±2.163, P=0.001; metastatic cancer: 6.710±2.369, non-metastatic cancer: 8.110±1.595, P=0.028). Conclusion Our study showed that ZMYND8 is regulated by GR, and ZMYND8 is a cancer promoter in prostate cancer. Key words: Zinc finger MYND-type containing 8; Glucocorticoid receptor; Prostate cancer; Metastasis; Castration-resistance
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
